Dr Jeffrey Weber and colleagues at the University of Kiel in Germany have published an article that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab. These monoclonal antibodies, directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152), have been investigated in metastatic melanoma and other cancers and have shown promising results. Ipilimumab has been approved for use in patients with metastatic melanoma. Both drugs have similar mechanisms of action, but are manufactured by different companies. Ipilimumab is an immunoglobulin G1 with a plasma half-life of 12-14 days. Tremelimumab is an immunoglobulin G2 with a plasma half-life of 22 days. Read more here.
Study mentioned: Weber JS, et al. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012 Jul 20;30(21):2691-7. Epub 2012 May 21. PMID: 22614989
No comments:
Post a Comment